Automated brightfield break-apart in situ hybridization (ba-ISH) application: ALK and MALT1 genes as models

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

Manabu Soda, Young Lim Choi, Munehiro Enomoto et al. · Nature · 2007 · 5.4K citations

Medicine, Molecular Biology, Oncology +14

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

Antonio C. Wolff, M. Elizabeth H. Hammond, Jared N. Schwartz et al. · Journal of Clinical Oncology · 2006 · 4.5K citations · Full text

Medicine, Oncology, Pathology +11

Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066

E.L. Kwak, D. Ross Camidge, John L. Clark et al. · Journal of Clinical Oncology · 2009 · 205 citations

Medicine, Oncology, Pharmacology +13

Antibody Elution Method for Multiple Immunohistochemistry on Primary Antibodies Raised in the Same Species and of the Same Subtype

Daniel Pirici, Laurenţiu Mogoantă, Samir Kumar‐Singh et al. · Journal of Histochemistry & Cytochemistry · 2009 · 147 citations · Full text

Medicine, Pathology, Antibody Engineering +15

Development of automated brightfield double In Situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence In Situ hybridization (FISH)

Hiroaki Nitta, Beatrice Hauss‐Wegrzyniak, Megan Lehrkamp et al. · Diagnostic Pathology · 2008 · 111 citations · Full text

Medicine, Molecular Biology, Oncology +17